Document:

Amendment No. 1 to Extended Joint Development Agreement

			
	 Exhibit 10.72

 
 CONFIDENTIAL TREATMENT
REQUESTED

  

 AMENDMENT NO. 1 TO 

EXTENDED JOINT DEVELOPMENT AGREEMENT 
 This Amendment No. 1 to Extended Joint Development Agreement (this “Amendment”) is entered into as of February 3, 2011 (the “Effective Date”), by and between
Philips Medical Systems Nederland B.V. (“Philips”) and Hansen Medical, Inc. 
 R E C I T A L S

 WHEREAS, Philips and Hansen previously entered into that certain Extended Joint Development Agreement, effective
November 15, 2009 (the “Agreement”); and 
 WHEREAS, Philips and Hansen desire to amend the Agreement in
accordance with the terms of this Amendment. 
 NOW, THEREFORE, in consideration for the agreements set forth below and for good
and valuable consideration, receipt of which is hereby acknowledged, Philips and Hansen hereby agree to amend the Agreement as follows and the parties hereto agree as follows: 
 A M E N D M E N T 
 1. Definitions. Except as
otherwise provided herein, capitalized terms used in this Amendment shall have the definitions set forth in the Agreement. 
 2. Amendment of Section 2.1.1. Two new sentences are hereby added to the end of Section 2.1.1 as follows: 
 “As part of the Project, and subject to the terms and conditions hereof, Hansen and Philips will reasonably cooperate towards the development of a [***] product [***] that will enhance the [***]
experience with the [***] and provide at least one [***] when used with compatible [***].” 
 “Philips and Hansen
will work together to [***], as will be further detailed in an update of the Annex 1 (Project Description) to this Agreement to be agreed upon by the Steering Committee as set forth in Section 3 of this Agreement, as contemplated in the
definition of “Project Description” in Section 1.” 
 3. Amendment of
Section 2.1.2. The last sentence of Section 2.1.2 of the Agreement is hereby amended and restated in its entirety as follows: 

  
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND 
 SEPARATELY FILED WITH THE COMMISSION 

			
	CONFIDENTIAL TREATMENT REQUESTED

  

 “Philips will have no right to any Sales Fees for systems sold and delivered to
the end customer after [***] (which number of [***] shall be increased to [***] after such time as [***] hereunder are [***]) from date of first commercial shipment of the Vascular System.” 

4. Amendment of Section 2.1.3. Section 2.1.3 of the Agreement is hereby amended and restated in its
entirety as follows: 
 “The System Sales Fees hereunder will be [***] (which amount shall be increased to [***] after
such time as [***] hereunder are [***] per Vascular System (excluding catheters) invoiced to the end customer, provided that no System Sales Fee will be due for systems that are delivered to customers only to replace a Vascular System (for warranty
or service reasons) for which appropriate System Sales Fee was already awarded to Philips.” 
 5.
Consideration. In consideration for the agreements set forth herein, Philips will make a non-refundable payment to Hansen US $6,000,000 within [***] of the Effective Date. For avoidance of doubt, the payment made under this Section 5 of
the Amendment will be included in the aggregate payments referenced in Sections 2.1.2 and 2.1.3. 
 6. Terms
of Agreement. Except as expressly modified hereby, all terms, conditions and provisions of the Agreement shall continue in full force and effect. 
 7. Conflicting Terms. In the event of any inconsistency or conflict regarding the subject matter of this Amendment between the Agreement and this Amendment, the terms, conditions and provisions of
this Amendment shall govern and control with regards to that subject matter of this Amendment. 
 8. Entire
Agreement. The Agreement, as amended by the Amendment, constitutes the entire and exclusive agreement between the parties with respect to the subject matter thereof. All previous discussions and agreements with respect to this subject matter are
superseded by the Agreement, as amended by this Amendment. This Amendment may be executed in one or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same instrument. Facsimile
counterparts shall be deemed to be originals. 

  
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND 
 SEPARATELY FILED WITH THE COMMISSION 

			
	CONFIDENTIAL TREATMENT REQUESTED

  

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the Effective Date.

 PHILIPS MEDICAL SYSTEMS NEDERLAND B.V. 
  

									
	By:	 	 /s/ Bert Van Meurs
	 		 	By:	 	 /s/ John Van Soerland

					
	Name:	 	 Bert Van Meurs
	 		 	Name:	 	 John Van Soerland

					
	Title:	 	 Senior Vice President
	 		 	Title:	 	 Senior Director

 HANSEN MEDICAL, INC. 
  

									
	 By:
	 	 /s/ Bruce J. Barclay
	 		 		 	
					
	 Name:
	 	 Bruce J Barclay
	 		 		 	
					
	 Title:
	 	 Chief Executive Officer
	 		 		 	

 [SIGNATURE PAGE TO AMENDMENT
NO. 1 TO EXTENDED JOINT DEVELOPMENT AGREEMENT]Amendment No. 1 to Patent and Technology License and Purchase Agreement

 Exhibit 10.74 

 

			
	 CONFIDENTIAL TREATMENT REQUESTED
	  	EXECUTION COPY

 AMENDMENT NO. 1 TO PATENT AND TECHNOLOGY LICENSE AND PURCHASE 

AGREEMENT 

This Amendment No. 1 (this “Amendment”) is made as of April 7, 2011 by and between Hansen Medical, Inc., a
company duly incorporated under the laws of the State of Delaware, having its registered office at 800 East Middlefield Road, Mountain View, CA 94043, USA (hereinafter referred to as “Hansen”), and Koninklijke Philips Electronics
N.V., a company duly incorporated under the laws of The Netherlands, having its registered office in Eindhoven, The Netherlands and Philips Medical Systems Nederland B.V., a private company with limited liability and a Philips Healthcare company,
having its registered office and its principal place of business at Veenpluis 4-6, 5684 PC, Best, The Netherlands (acting jointly and severally and hereinafter individually and collectively referred to as “Philips”) (hereinafter
referred to collectively as the “Parties” and individually as a “Party”). 

WHEREAS, Parties entered into a Patent and Technology License Purchase Agreement on February 3, 2011 (the
“Agreement”). 
 WHEREAS, Parties wish to amend the Agreement to correct a
typographical error in clause (b) under Section 4.2 of the Agreement. 
 NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties hereby agree as follows: 
  

	1.	 SECTION 4.2.

 Clause (b) of Section 4.2 of the Agreement is hereby amended in its entirety as follows: 

“Philips hereby grants to Hansen (with respect to the foregoing license granted to Hansen) and to SPE (with respect to the foregoing
license granted to SPE) the option (which must be exercised within [***] to convert the foregoing license granted to Hansen and SPE in clause (a) from a nonexclusive license to an exclusive license (except with respect to the SDOF Endoluminal
Robotics Field, SDOF Orthopedics Robotics Field and SDOF Vascular Robotics Field, for which Philips acknowledges that the licenses granted to Philips in Section 2.1.1 of the SPE-Philips Agreement and Section 2.1.1 of this Agreement shall
terminate), exercisable by written notice to Philips and payment of [***] by Hansen and [***] by SPE with respect to the Vascular Buy Back Field, [***] by Hansen and [***] by SPE with respect to the Endoluminal Buy Back Field or [***] by Hansen and
[***] by SPE with respect to the Orthopedics Buy Back Field (“Buy Back Price”); and” 
  

	2.	 GENERAL.

 Except as expressly modified by this Amendment, all terms, conditions and provisions of the
Agreement shall continue in full force and effect as set forth in the Agreement. Each Party agrees that the Agreement, as amended by this Amendment, constitutes the complete and exclusive statement of the agreement between the Parties, and
supersedes all prior proposals and understandings, oral and written, relating to the subject matter contained herein. This Amendment shall not be modified or rescinded except in a writing signed by the Parties. 

 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

			
	CONFIDENTIAL TREATMENT REQUESTED	  	EXECUTION COPY

  

 AS WITNESS, the Parties have caused this Agreement to be signed on the date first written above.

 FOR HANSEN: 
 Hansen Medical,
Inc. 

	
	
	 /s/ Bruce Barclay

	 (signature)

	 Name: Bruce Barclay

	 Title: President and CEO

 FOR PHILIPS: 
 Koninklijke Philips Electronics N.V. 

	
	
	 /s/ Ruud Peters

	 (signature)

	 Name: Ruud Peters

	 Title: Chief Intellectual Property Officer

 Philips Medical Systems Nederland B.V. 

	
	
	 /s/ T.G.W. Winkels

	 (signature)

	 Name: T.G.W. Winkels

	 Title: VP NBD BuixrTransition Agreement

 Exhibit 10.82 
 HANSEN MEDICAL, INC. 

August 29, 2011 
 Frederic
H. Moll, M.D. 
 Dear Fred: 
 This letter (the “Agreement”) confirms the agreement between you and Hansen Medical, Inc. (the “Company”) regarding your resignation as an employee of the Company. If you sign and do
not revoke this Agreement, you will be eligible for the benefits described in Sections 4 and 5 of this Agreement. 
 1.
Transition Date. You and the Company have agreed that you will resign from your employment with the Company effective August 31, 2011 (the “Transition Date”). Simultaneously with the execution of this Agreement, you and the
Company are entering into a Consulting Agreement, a copy of which is attached as Exhibit A hereto, pursuant to which you will provide transition services to the Company (the “Consulting Agreement”). Additionally, we anticipate that you
will continue to serve as the non-executive Chairman of the Company’s Board of Directors until December 31, 2011, and then continue to serve as a member of the Company’s Board of Directors. By signing this Agreement, you hereby resign
as non-executive Chairman of the Board of Directors (but not as a member of the Board of Directors), effective as of December 31, 2011. 
 2. Effective Date and Revocation. You have up to 21 days after you receive this Agreement to review it. You are advised to consult an attorney of your own choosing before signing this Agreement.
Furthermore, you have up to seven days after you sign this Agreement to revoke it. If you wish to revoke this Agreement after signing it, you may do so by delivering a letter of revocation to me. If you do not revoke this Agreement, the eighth day
after the date you sign it will be the “Effective Date.” Because of the seven-day revocation period, no part of this Agreement or the Consulting Agreement will become effective or enforceable until the Effective Date. 

3. Salary and Vacation Pay. On the Transition Date, the Company will pay you all of your salary earned through the Transition Date
which is approximately equal to $9,984.00 (less all applicable withholding taxes), and all of your accrued but unused vacation time or PTO through the Transition Date which is approximately equal to $35,562.18 (less all applicable withholding
taxes). In addition, you will receive reimbursement for reasonable and necessary expenses incurred by you on behalf of the Company during the period ending on the Transition Date in accordance with the Company’s expense reimbursement policy and
reimbursement for any unused amounts deposited in the Company’s 2006 Employee Stock Purchase Plan. You acknowledge that the only payments and benefits that you are entitled to receive from the Company in the future are those specified in this
Agreement and the Consulting Agreement and any compensation you may be entitled to receive in accordance with the Company’s standard compensation arrangements for non-employee directors. 

 NAME 
 DATE 
  Page
 2
 
  

 4. Continued Benefits. You will receive information about
your right to continue your group health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) after the Transition Date. In order to continue your coverage, you must file the required election form. If you
sign and do not revoke this Agreement and elect to continue group health insurance coverage, then the Company will pay the monthly premium under COBRA for yourself and, if applicable, your dependents until the earliest of (a) the end of the
period of 12 months following the month in which the Transition Date occurs, (b) the expiration of your continuation coverage under COBRA or (c) the first day of your eligibility to participate in a comparable group health plan maintained
by a subsequent employer. You agree to notify the Company immediately if clause (c) becomes applicable. In addition, if you sign and do not revoke this Agreement, then on the sixtieth
(60th) day following the Transition Date, the Company
will make a lump sum payment to you of $1,485.00 (less all applicable withholding taxes). The Company shall also reimburse you for reasonable out of pocket legal expenses incurred by you in connection with the review of this Agreement and the
Consulting Agreement, up to a maximum of $13,000. Finally, the Company will allow you to keep your Company-issued laptop computer. 
 5. Equity Awards. 
 (a) You hold the following equity awards, including
options to purchase shares of the Company’s Common Stock (each, an “Option” and collectively, the “Options”) and restricted stock units (each, an “RSU” and collectively, the “RSUs”): 

 

																					
	 Date of Grant
	 	Type of Award	 	Number of
Shares 
Granted	 	 	Exercise Price
Per
Share	 	 	Number of Shares
Vested as of the
Transition Date	 	 	Number of Shares
Unvested as of the
Transition Date	 	 	Expiration Date
	2/14/07	 	Option	 	 	60,000	  	 	$	17.08	  	 	 	60,000	  	 	 	0	  	 	2/13/14
	5/6/08	 	Option	 	 	200,000	  	 	$	18.94	  	 	 	162,497	  	 	 	37,503	  	 	5/5/15
	3/3/09	 	Option	 	 	100,000	  	 	$	3.26	  	 	 	60,416	  	 	 	39,584	  	 	3/2/16
	8/11/10	 	Option	 	 	600,000	  	 	$	1.58	  	 	 	175,000	  	 	 	425,000	  	 	8/10/17
	10/26/10	 	RSU	 	 	52,500	  	 	 	n/a	  	 	 	34,125	1 	 	 	0	  	 	n/a
	12/20/10	 	RSU	 	 	87,500	  	 	 	n/a	  	 	 	0	  	 	 	87,500	  	 	n/a

  

	1 	 The remaining 18,375 unvested RSUs were cancelled on February 27, 2011. 

 NAME 
 DATE 
  Page
 3
 
  

 (b) In consideration of your execution of this Agreement, all of the Options that are
unvested as of the Transition Date (as set forth in the table above) shall immediately become fully vested and exercisable, effective as of the Effective Date. Following the Transition Date, the Options will remain exercisable in accordance with
their terms during the term of the Consulting Agreement or your service as a member of the Board of Directors (notwithstanding any contrary provision of the applicable Option Agreement governing the Option) and, after termination of such service,
for the period of time specified in the Company’s 2006 Equity Incentive Plan (the “Plan”) and the applicable Stock Option Agreement for exercisability following termination of service; provided, however, that the Options will in no
event remain exercisable beyond their applicable expiration dates and will be subject to earlier termination in accordance with the Plan. Please note that to the extent the Options remain incentive stock options following the application of the
accelerated vesting described in this Subsection (b), they will automatically become nonstatutory stock options three months after the Transition Date. 
 (c) The 34,125 vested RSUs granted on October 26, 2010 will be settled in accordance with their terms on the first “permissible trading day” (as defined in the applicable Restricted Stock
Unit Agreement) but in any event no later than March 15, 2012, and without regard to whether you have terminated service pursuant to the Consulting Agreement or as a member of the Board of Directors. 

(d) You and the Company agree that the RSUs granted on December 20, 2010 will vest in early 2012 in accordance with their terms
based on the achievement of the performance goals applicable to those RSUs, provided that your service pursuant to the Consulting Agreement or as a member of the Board of Directors has not terminated prior to the date the vesting decision is made by
the Board of Directors or its Compensation Committee. In addition, you will be eligible to vest in the remainder of the December 20, 2010 RSUs on the terms described in the Consulting Agreement. Any December 20, 2010 RSUs that do not vest
will be cancelled on the earlier of March 1, 2012 or the date you are no longer eligible to vest in such RSUs. Any December 20, 2010 RSUs that vest will be settled on the first “permissible trading day” (as defined in the
applicable Restricted Stock Unit Agreement) that occurs on or after the date of vesting but in any event no later than March 15, 2012, and without regard to whether you have terminated service pursuant to the Consulting Agreement or as a member
of the Board of Directors. 
 (e) Except as set forth in this Paragraph 5, the Stock Option Agreements governing the Options and
the Restricted Stock Unit Agreements governing the RSUs will remain in full force and effect, and you agree to remain bound by those Agreements. 

 NAME 
 DATE 
  Page
 4
 
  

 6. Release of All Claims. In consideration for receiving the severance benefits
described in Paragraphs 4 and 5 above, to the fullest extent permitted by applicable law, you waive, release and promise never to assert any claims or causes of action, whether or not now known, against the Company or its predecessors, successors or
past or present subsidiaries, stockholders, directors, officers, employees, consultants, attorneys, agents, assigns and employee benefit plans with respect to any matter, including (without limitation) any matter related to your employment with the
Company or the termination of that employment, including (without limitation) claims to attorneys’ fees or costs, claims of wrongful discharge, constructive discharge, emotional distress, defamation, invasion of privacy, fraud, breach of
contract or breach of the covenant of good faith and fair dealing and any claims of discrimination or harassment based on sex, age, race, national origin, disability or any other basis under Title VII of the Civil Rights Act of 1964, the
California Fair Employment and Housing Act, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act and all other laws and regulations relating to employment. However, this release covers only those claims that arose
prior to the execution of this Agreement and only those claims that may be waived by applicable law. Execution of this Agreement does not bar any claim that arises hereafter, including (without limitation) a claim for breach of this Agreement or any
claim to indemnification under Section 2802 of the California Labor Code. Notwithstanding the foregoing, you are not hereby releasing the Company from any of the following claims: (a) any rights or claims for indemnification you may have
pursuant to any written indemnification agreement with the Company to which you are a party, the charter, bylaws or other governing documents of the Company, or under applicable law, or under directors and officers liability, errors and omissions or
other insurance policies including any run-off endorsement relating thereto, or otherwise; (b) any rights or claims to contribution you may have in the event of the entry of judgment against you as a result of any act or failure to act for
which both you and the Company (or its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent or subsidiary entities, insurers, affiliates or assigns) are jointly responsible; or (c) any
vested rights under a Company-sponsored benefit plan (in this regard, you acknowledge and agree that Paragraph 5 of this Agreement accurately reflects the terms of your outstanding equity awards). The Company acknowledges its continuing obligations
to you under the Indemnity Agreement between you and the Company, a copy of which is attached hereto as Exhibit B. 
 7.
Waiver. You expressly waive and release any and all rights and benefits under Section 1542 of the California Civil Code (or any analogous law of any other state), which reads as follows: 

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of
executing the release, which if known by him or her must have materially affected his or her settlement with the debtor. 
 8.
No Admission. Nothing contained in this Agreement will constitute or be treated as an admission by you or the Company of liability, any wrongdoing or any violation of law. 

 NAME 
 DATE 
  Page
 5
 
  

 9. Other Agreements. As a reminder, at all times in the future, you will remain
bound by (i) the Consulting Agreement, and (ii) your Proprietary Information and Inventions Agreement with the Company, which you signed on November 11, 2002, and a copy of which is attached as Exhibit C. Except for the
Company’s letter to you dated August 24, 2011 related to the advancement of expenses pursuant to your Indemnity Agreement or as expressly provided in this Agreement, this Agreement constitutes the entire agreement between you and the
Company regarding the subject matter of this Agreement and renders null and void all prior and contemporaneous written or oral agreements between you and the Company regarding the subject matter of this Agreement, including without limitation, the
Retention Agreement between you and the Company dated June 28, 2010 (except for Section 5 thereof, which shall survive the termination of that agreement), and your offer letter with the Company dated October 21, 2002. For avoidance of
doubt, while not expressly related to the subject matter of this Agreement, the Technology Assignment Agreement between you and the Company dated as of November 7, 2002 and a copy of which is attached as Exhibit D will remain in full force and
effect. This Agreement may be modified only in a written document signed by you and a duly authorized officer of the Company. 

10. Severability. If any term of this Agreement is held to be invalid, void or unenforceable, the remainder of this Agreement will
remain in full force and effect and will in no way be affected, and the parties will use their best efforts to find an alternate way to achieve the same result. 
 11. Choice of Law. This Agreement will be construed and interpreted in accordance with the laws of the State of California (other than their choice-of-law provisions). 

12. Execution. This Agreement may be executed in counterparts, each of which will be considered an original, but all of which
together will constitute one agreement. Execution of a facsimile copy will have the same force and effect as execution of an original, and a facsimile signature will be deemed an original and valid signature. 

 NAME 
 DATE 
  Page
 6
 
  

 Please indicate your agreement with the above terms by signing below. 

 

			
	Very truly yours,
	
	HANSEN MEDICAL, INC.
		
	By:	 	 /S/ BRUCE J BARCLAY

		 	Name: Bruce J Barclay
		 	Title:  Chief Executive Officer

 I agree to the terms of this Agreement, and I am voluntarily signing this release of all claims. I acknowledge that
I have read and understand this Agreement, and I understand that I cannot pursue any of the claims and rights that I have waived in this Agreement at any time in the future. 

 

			
	 /S/ FREDERIC H. MOLL, M.D.
	 	
	Signature of Frederic H. Moll, M.D.	 	
		
	Dated: August 29, 2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]